Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CRBPthis companyCorbus Pharmaceuticals Holdings, Inc.	$3.57	-1.38×	0.73×	0×	-1.04×	-49.7%	0.0%	0.0%	0.0%	-53.2%	-57.2%	-59.5%	0.01×	0.34×	0×	8.07×	0.0%	1	-6.62	2	B-
ALECAlector, Inc.	$2.43	-1.12×	5.24×	7.63×	-0.99×	-108.0%	54.1%	-692.8%	-679.2%	-466.3%	-62.5%	-114.6%	1.18×	0.22×	0×	3.83×	0.0%	2	-7.33	2	C
CRDFCardiff Oncology, Inc.	$0.82	-4.07×	4.14×	316.73×	-3.81×	-96.7%	100.0%	-8256.3%	-7732.0%	-101.0%	-105.9%	-20.2%	0.02×	0.37×	0×	3.67×	0.0%	2	-16.02	2	C
ELTXElicio Therapeutics, Inc.	$1.63	-3.09×	74.5×	0×	-3.16×	-85.8%	0.0%	0.0%	0.0%	-2418.8%	-201.0%	-30.3%	8.87×	0.11×	-33.29×	2.38×	0.0%	2	-14.29	1	D+
PEPGPepGen Inc.	$2.44	-3.07×	1.86×	0×	-2.62×	-56.9%	0.0%	0.0%	0.0%	-60.8%	-56.9%	-29.8%	0.12×	0.49×	0×	11.94×	0.0%	2	-0.25	2	C+
RANIRani Therapeutics Holdings, Inc.	$0.56	-3×	2.7×	54.68×	-2.02×	-41.3%	44.9%	-2346.0%	-1817.1%	-89.9%	-80.6%	-21.1%	0.13×	0.38×	-13.25×	4.21×	0.0%	5	-2.49	2	C
Peer median	—	-3.07×	4.14×	7.63×	-2.62×	-85.8%	44.9%	-692.8%	-679.2%	-101.0%	-80.6%	-29.8%	0.13×	0.37×	0×	3.83×	0.0%	2	-7.33	2	—